Alzamend Neuro Inc carries no debt; cash flow comfortably covers obligations.

Alzamend Neuro Inc's free cash flow has increased -18.40% from $-8.42M last year to $-6.87M, signaling increasing performance

Alzamend Neuro Inc's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Alzamend Neuro Inc has insufficient data to evaluate this check.

Alzamend Neuro Inc has a net cash position, so leverage is healthy.

Alzamend Neuro Inc earns at least as much interest as it pays. Interest obligations are fully covered.

Alzamend Neuro Inc has insufficient data to evaluate this check.

Alzamend Neuro Inc's short-term assets of $1.76M exceed its short-term liabilities of $1.35M

Alzamend Neuro Inc's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Alzamend Neuro Inc's return on equity of -277.71%, is lower than 15.00%, indicating bad performance

Alzamend Neuro Inc's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Alzamend Neuro Inc had positive net income in only 0 out of 5 years, indicating unstable earnings

Alzamend Neuro Inc has negative free cash flow, indicating the company is burning cash rather than generating it

Alzamend Neuro Inc has negative free cash flow, indicating cash burn

Alzamend Neuro Inc's yearly earnings has decreased 94.30% since last year from $-4.51M to $-8.77M, signaling decreasing performance

Alzamend Neuro Inc's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -1.20K% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Alzamend Neuro Inc has insufficient revenue history to calculate 3-year revenue CAGR.

Alzamend Neuro Inc had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Alzamend Neuro Inc had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Alzamend Neuro Inc has insufficient data to evaluate this check.

Alzamend Neuro Inc has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Alzamend Neuro Inc is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Alzamend Neuro Inc has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Alzamend Neuro Inc has insufficient data to evaluate this check.

Alzamend Neuro Inc has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Alzamend Neuro Inc has a price-to-book ratio of 6.65x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Alzamend Neuro Inc has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue